Move over probiotics, Coronado Biosciences has 'Proparasites' (SeekingAlpha) - May 14, 2012 - Coronado announced plans to begin a P2b trial in Crohn's involving around 200 pts in 2Q 2012; Report European (Falk) P2 Crohn's study in 1Q 2013; Report US P2b Crohn's study in mid 2013
Anticipated P2b trial initiation • Inflammatory Bowel Disease
|
|
TSO And Crohn's Disease
29 patients with active Crohn's disease (defined by a CDAI > 220 score -- an objective measure of Crohn's disease activity). Patients took TSO eggs (2,500 eggs) in a solution every three weeks for 24 weeks. Patients maintained diaries of symptoms, and disease activity was measured by CDAI. At 24 weeks, treatment with TSO was associated with significant improvement: 79.3% patients experiencing a response (decrease in CDAI > 100 points, or CDAI
Coronado announced plans to begin a Phase II trial in Crohn's involving around 200 patients.
TSO And Ulcerative Colitis
This randomized, double-blind, placebo-controlled study evaluated TSO in 54 patients with active ulcerative colitis (determined by the ulcerative colitis disease activity index). Clinical trial duration was 24 weeks (treatment arm and placebo arm with crossover phase). Without going into the complicated details of the trial design, the results (see the graph below) show the difference in positive treatment response between the TSO group vs. the placebo group. The worm TSO group had a more-than-doubled percentage improvement compared with the placebo group.
|